Table of Contents:
I. Nora’s Blog
II. Coronavirus Disease 2019 (COVID-19): Information for NIH Applicants and Recipients of NIH Funding
III. NIDA RFAs and PARs
IV. NIDA Notices of Special Interest
--------------
I. Nora’s Blog (The Blog of the Director of the National Institute on Drug Abuse, NIDA)
II. Coronavirus Disease 2019 (COVID-19): Information for NIH Applicants and Recipients of NIH Funding https://grants.nih.gov/policy/natural-disasters/corona-virus.htm
III. NIDA RFAs and PARs:
RFA-DA-21-005 (R61/R33) Exploiting Omics Assays to Investigate Molecular Regulation of Persistent HIV in Individuals with Substance Use Disorder (Clinical Trial Optional)
Application Receipt Date(s): August 13, 2020
RFA-DA-21-005 Exploiting in vivo or in situ imaging approaches to understand HIV-relevant processes in the context of substance use disorders (R61/R33 Clinical Trials Optional)
Application Receipt Date(s): July 14, 2020
RFA-DA-19-003 (R61/R33) Exploiting Omics Assays to Investigate Molecular Regulation of Persistent HIV in Individuals with Substance Use Disorder (Clinical Trial Optional)
Application receipt date: July 17, 2020
RFA-DA-21-004 (R21/R33) Exploring the Roles of Biomolecular Condensates (BMCs) in HIV replication, latency, or pathogenesis in the context of substance use disorders (Clinical Trial Not Allowed)
Application receipt date: July 20, 2020
PAR-20-147 Extracellular RNA carrier subclasses in processes relevant to Substance Use Disorders or HIV infection (R01- Clinical Trial Not Allowed) Application Receipt Date(s): October 13, 2020, March 15, 2021, October 13, 2021, March 15, 2022, October 13, 2022, March 15, 2023
PAR-20-148 Extracellular RNA carrier subclasses in processes relevant to Substance Use Disorders or HIV infection (R21- Clinical Trial Not Allowed)
Application Receipt Date(s): October 13, 2020, March 15, 2021, October 13, 2021, March 15, 2022, October 13, 2022, March 15, 2023 Standard dates apply. The first standard due date for this FOA is October 5, 2020
PAR-18-789 Genetic analysis of non-human animal models to understand the genomic architecture of substance use disorders and addictive behaviors (U01 Clinical Trial Not Allowed)
Application Receipt Dates: August 21, 2020, March 19, 2021
PAR-19-278 (R21/R33) Exploiting Genome or Epigenome Editing to Functionally Validate Genes or Variants Involved in Substance Use Disorders
Application receipt dates: June 24, 2020, December 18, 2020, June 24, 2021, December 17, 2021
PAR-19-223 Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (Application receipt dates: October 19, 2020, October 19, 2021, by 5:00 PM local time of applicant organization).
IV. NIDA Notices of Special Interest:
NOT-HL-20-746 Notice of Special Interest (NOSI): NHLBI and NIDA Announce Availability of Administrative Supplements for HEAL Awardees to Address Sleep Impairments in OUD Treatment Response and Recovery Outcomes
NOT-DA-20-017 Harnessing computational tools for sophisticated analyses of Substance Use Disorder-related behaviors
NOT-DA-20-030 Human Molecular Genetics of Substance Use Disorders
NOT-DA-20-020 Going Global: Using Gene Network Analyses to Understand the Etiology of SUD
NOT-DA-20-031 Transcriptomic, epigenomic, regulatory RNA or functional genomic research in Substance Use Disorders
NOT-DA-19-041 The Application of Big Data Analytics to Drug Abuse Research
NOT-DA-19-038 Gene-Environment Interplay in Substance Use Disorders
NOT-DA-20-046 Notice of Special Interest (NOSI): Neuroimmune Signaling and Function in Substance Use Disorders
NOT-DA-20-018 Notice of Special Interest (NOSI): Exploring the Roles of Biomolecular Condensates (BMCs) in Substance Use Disorder and/or HIV-related processes
NOT-DA-20-021 Notice of Special Interest (NOSI):Sleep and Substance Use Disorders
NOT-DA-20-039 Notice of Special Interest (NOSI): Effects of Cannabis Use and Cannabinoids on the Developing Brain
NOT-DA-20-046 Notice of Special Interest (NOSI): Neuroimmune Signaling and Function in Substance Use Disorders
NOT-DA-20-012 Notice of Special Interest (NOSI): Biomarkers and Biotypes of Drug Addiction
---------
The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L in the message body of the email - You will receive a confirmation email if successful. If you have problems contact jpollock@mail.nih.gov 301-435-1309
http://list.nih.gov/cgi-bin/wa?SUBED1=nida_neuro_science-l&A=1&X=6F4BAE4CF706755A29&Y=nidaneurosc%40mail.nih.gov&A=0
